Neoadjuvant dual immuno-combination therapy with anti-LAG3 and anti-PD-1 antibodies is feasible and safe for resectable non-small cell lung cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 28-Jul-2025 03:11 ET (28-Jul-2025 07:11 GMT/UTC)